Therapy-related myelodysplasia and leukemia occur infrequently following VP-16 priming and autotransplantation without total body irradiation

E. Copelan, S. Hoshaw-Woodard, P. Elder, S. Penza, Sherif Farag, G. Marcucci, T. Lin, S. Ezzone, M. D. Scholl, T. Bechtel, S. Lemeshow, B. Avalos

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The use of VP-16 for stem cell mobilization has been cited as a significant risk factor for the development of therapy-related myelodysplasia/leukemia (tMDS/tAML) following autologous transplantation. The present study analyzed a large cohort of patients who underwent autotransplantation following stem cell mobilization with VP-16 and radiation-free preparation in order to determine the risk of tMDS/tAML. The estimated incidence of 9.9% at 7 years suggests that in the absence of TBI, VP-16 priming is not associated with an increased incidence of tMDS/tAML.

Original languageEnglish (US)
Pages (from-to)85-87
Number of pages3
JournalBone Marrow Transplantation
Volume34
Issue number1
DOIs
StatePublished - Jul 2004
Externally publishedYes

Fingerprint

Autologous Transplantation
Whole-Body Irradiation
Etoposide
Hematopoietic Stem Cell Mobilization
Leukemia
Incidence
Therapeutics
Radiation

Keywords

  • Autotransplantation
  • Secondary AML
  • VP-16

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Therapy-related myelodysplasia and leukemia occur infrequently following VP-16 priming and autotransplantation without total body irradiation. / Copelan, E.; Hoshaw-Woodard, S.; Elder, P.; Penza, S.; Farag, Sherif; Marcucci, G.; Lin, T.; Ezzone, S.; Scholl, M. D.; Bechtel, T.; Lemeshow, S.; Avalos, B.

In: Bone Marrow Transplantation, Vol. 34, No. 1, 07.2004, p. 85-87.

Research output: Contribution to journalArticle

Copelan, E, Hoshaw-Woodard, S, Elder, P, Penza, S, Farag, S, Marcucci, G, Lin, T, Ezzone, S, Scholl, MD, Bechtel, T, Lemeshow, S & Avalos, B 2004, 'Therapy-related myelodysplasia and leukemia occur infrequently following VP-16 priming and autotransplantation without total body irradiation', Bone Marrow Transplantation, vol. 34, no. 1, pp. 85-87. https://doi.org/10.1038/sj.bmt.1704532
Copelan, E. ; Hoshaw-Woodard, S. ; Elder, P. ; Penza, S. ; Farag, Sherif ; Marcucci, G. ; Lin, T. ; Ezzone, S. ; Scholl, M. D. ; Bechtel, T. ; Lemeshow, S. ; Avalos, B. / Therapy-related myelodysplasia and leukemia occur infrequently following VP-16 priming and autotransplantation without total body irradiation. In: Bone Marrow Transplantation. 2004 ; Vol. 34, No. 1. pp. 85-87.
@article{4015e804902e4f3ea8f153d04e0d8b9a,
title = "Therapy-related myelodysplasia and leukemia occur infrequently following VP-16 priming and autotransplantation without total body irradiation",
abstract = "The use of VP-16 for stem cell mobilization has been cited as a significant risk factor for the development of therapy-related myelodysplasia/leukemia (tMDS/tAML) following autologous transplantation. The present study analyzed a large cohort of patients who underwent autotransplantation following stem cell mobilization with VP-16 and radiation-free preparation in order to determine the risk of tMDS/tAML. The estimated incidence of 9.9{\%} at 7 years suggests that in the absence of TBI, VP-16 priming is not associated with an increased incidence of tMDS/tAML.",
keywords = "Autotransplantation, Secondary AML, VP-16",
author = "E. Copelan and S. Hoshaw-Woodard and P. Elder and S. Penza and Sherif Farag and G. Marcucci and T. Lin and S. Ezzone and Scholl, {M. D.} and T. Bechtel and S. Lemeshow and B. Avalos",
year = "2004",
month = "7",
doi = "10.1038/sj.bmt.1704532",
language = "English (US)",
volume = "34",
pages = "85--87",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Therapy-related myelodysplasia and leukemia occur infrequently following VP-16 priming and autotransplantation without total body irradiation

AU - Copelan, E.

AU - Hoshaw-Woodard, S.

AU - Elder, P.

AU - Penza, S.

AU - Farag, Sherif

AU - Marcucci, G.

AU - Lin, T.

AU - Ezzone, S.

AU - Scholl, M. D.

AU - Bechtel, T.

AU - Lemeshow, S.

AU - Avalos, B.

PY - 2004/7

Y1 - 2004/7

N2 - The use of VP-16 for stem cell mobilization has been cited as a significant risk factor for the development of therapy-related myelodysplasia/leukemia (tMDS/tAML) following autologous transplantation. The present study analyzed a large cohort of patients who underwent autotransplantation following stem cell mobilization with VP-16 and radiation-free preparation in order to determine the risk of tMDS/tAML. The estimated incidence of 9.9% at 7 years suggests that in the absence of TBI, VP-16 priming is not associated with an increased incidence of tMDS/tAML.

AB - The use of VP-16 for stem cell mobilization has been cited as a significant risk factor for the development of therapy-related myelodysplasia/leukemia (tMDS/tAML) following autologous transplantation. The present study analyzed a large cohort of patients who underwent autotransplantation following stem cell mobilization with VP-16 and radiation-free preparation in order to determine the risk of tMDS/tAML. The estimated incidence of 9.9% at 7 years suggests that in the absence of TBI, VP-16 priming is not associated with an increased incidence of tMDS/tAML.

KW - Autotransplantation

KW - Secondary AML

KW - VP-16

UR - http://www.scopus.com/inward/record.url?scp=3543053426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3543053426&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1704532

DO - 10.1038/sj.bmt.1704532

M3 - Article

C2 - 15156164

AN - SCOPUS:3543053426

VL - 34

SP - 85

EP - 87

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 1

ER -